Cantel Medical (CMD) 10-Q 1 Mar 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jan. 31, 2019	Feb. 28, 2019
Document and Entity Information
Entity Registrant Name	CANTEL MEDICAL CORP
Entity Central Index Key	19,446
Document Type	10-Q
Document Period End Date	Jan. 31, 2019
Amendment Flag	false
Current Fiscal Year End Date	--07-31
Entity Filer Category	Large Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	false
Entity Common Stock, Shares Outstanding		41,721,300
Document Fiscal Year Focus	2,019
Document Fiscal Period Focus	Q2

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Jan. 31, 2019	Jul. 31, 2018
Current assets:
Cash and cash equivalents	$ 71,031	$ 94,097
Accounts receivable, net of allowance for doubtful accounts of $1,498 and $1,149	127,093	118,642
Inventories, net	115,886	107,592
Prepaid expenses and other current assets	21,801	17,912
Total current assets	335,811	338,243
Property and equipment, net	164,836	111,417
Intangible assets, net	141,548	137,361
Goodwill	371,015	368,027
Other assets	5,140	5,749
Deferred income taxes	3,683	2,911
Total assets	1,022,033	963,708
Current liabilities:
Accounts payable	35,138	34,258
Compensation payable	21,681	30,595
Accrued expenses	28,132	28,525
Deferred revenue	27,136	28,614
Current portion of long-term debt	10,000	10,000
Income taxes payable	561	2,791
Total current liabilities	122,648	134,783
Long-term debt	227,577	187,302
Deferred income taxes	25,301	27,624
Other long-term liabilities	4,904	5,132
Total liabilities	380,430	354,841
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred Stock, par value $1.00 per share; authorized 1,000,000 shares; none issued	0	0
Common Stock, par value $0.10 per share; authorized 75,000,000 shares; issued 46,307,808 shares and outstanding 41,721,186 shares as of January 31, 2019; issued 46,243,582 shares and outstanding 41,706,084 shares as of July 31, 2018	4,631	4,624
Additional paid-in capital	192,202	184,212
Retained earnings	526,274	491,540
Accumulated other comprehensive loss	(17,096)	(11,456)
Treasury Stock, at cost; 4,586,622 shares as of January 31, 2019; 4,537,498 shares as of July 31, 2018	(64,408)	(60,053)
Total stockholders’ equity	641,603	608,867
Total liabilities and stockholders’ equity	$ 1,022,033	$ 963,708

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Jan. 31, 2019	Jul. 31, 2018
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts (in dollars)	$ 1,498	$ 1,149
Preferred Stock, par value (in dollars per share)	$ 1	$ 1
Preferred Stock, authorized (in shares)	1,000,000	1,000,000
Preferred Stock, issued (in shares)	0	0
Common Stock, par value (in dollars per share)	$ 0.10	$ 0.10
Common Stock, authorized (in shares)	75,000,000	75,000,000
Common Stock, issued (in shares)	46,307,808	46,243,582
Common Stock, outstanding (in shares)	41,721,186	41,706,084
Treasury Stock (in shares)	4,586,622	4,537,498

Condensed Consolidated Statemen

Condensed Consolidated Statements of Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Net sales
Net sales	$ 224,538	$ 213,034	$ 450,127	$ 425,800
Cost of sales
Cost of sales	119,863	111,799	240,203	223,906
Gross profit	104,675	101,235	209,924	201,894
Expenses:
Selling	33,198	30,922	67,156	62,522
General and administrative	37,358	32,188	73,893	64,284
Research and development	7,923	5,643	15,001	10,972
Total operating expenses	78,479	68,753	156,050	137,778
Income from operations	26,196	32,482	53,874	64,116
Interest expense, net	2,207	1,135	4,233	2,324
Other income, net	(1,313)	0	(1,313)	(1,138)
Income before income taxes	25,302	31,347	50,954	62,930
Income taxes	6,502	(1,141)	12,912	7,513
Net income	$ 18,800	$ 32,488	$ 38,042	$ 55,417
Earnings per common share:
Basic (in dollars per share)	$ 0.45	$ 0.78	$ 0.91	$ 1.33
Diluted (in dollars per share)	0.45	0.78	0.91	1.33
Dividends declared per common share (in dollars per share)	$ 0.10	$ 0.09	$ 0.10	$ 0.09
Product sales
Net sales
Net sales	$ 194,013	$ 186,484	$ 389,773	$ 374,449
Cost of sales
Cost of sales	100,418	94,144	199,728	189,243
Product service
Net sales
Net sales	30,525	26,550	60,354	51,351
Cost of sales
Cost of sales	$ 19,445	$ 17,655	$ 40,475	$ 34,663

Condensed Consolidated Statem_2

Condensed Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 18,800	$ 32,488	$ 38,042	$ 55,417
Other comprehensive loss (income):
Foreign currency translation	(417)	12,379	(5,640)	11,146
Total other comprehensive loss (income)	(417)	12,379	(5,640)	11,146
Comprehensive income	$ 18,383	$ 44,867	$ 32,402	$ 66,563

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Changes in Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Retained Earnings	Accumulated Other Comprehensive Income	Treasury stock, at cost
Beginning Balance (in shares) at Jul. 31, 2017		41,728,934
Beginning Balance at Jul. 31, 2017	$ 523,932	$ 4,619	$ 174,602	$ 407,590	$ (9,900)	$ (52,979)
Increase (Decrease) in Stockholders' Equity
Repurchases of shares (in shares)		(52,008)
Repurchases of shares	(5,822)					(5,822)
Stock-based compensation	1,851		1,851
Equity vestings/option exercises (in shares)		42,168
Equity vestings/option exercises	879	$ 5	874
Cancellations of restricted stock (in shares)		(1,315)
Cancellations of restricted stock	0
Dividends on common stock	0			0
Net income	22,929			22,929
Other (in shares)		88,100
Other	42	$ 10	32
Other comprehensive loss	(1,233)				(1,233)
Ending Balance (in shares) at Oct. 31, 2017		41,805,879
Ending Balance at Oct. 31, 2017	542,578	$ 4,634	177,359	430,519	(11,133)	(58,801)
Beginning Balance (in shares) at Jul. 31, 2017		41,728,934
Beginning Balance at Jul. 31, 2017	523,932	$ 4,619	174,602	407,590	(9,900)	(52,979)
Increase (Decrease) in Stockholders' Equity
Net income	55,417
Other comprehensive loss	11,146
Ending Balance (in shares) at Jan. 31, 2018		41,714,903
Ending Balance at Jan. 31, 2018	586,483	$ 4,624	180,083	459,462	1,246	(58,932)
Beginning Balance (in shares) at Oct. 31, 2017		41,805,879
Beginning Balance at Oct. 31, 2017	542,578	$ 4,634	177,359	430,519	(11,133)	(58,801)
Increase (Decrease) in Stockholders' Equity
Repurchases of shares (in shares)		(1,272)
Repurchases of shares	(131)					(131)
Stock-based compensation	2,739		2,739
Equity vestings/option exercises (in shares)		0
Equity vestings/option exercises	0	$ 0	0
Cancellations of restricted stock (in shares)		(1,604)
Cancellations of restricted stock	0
Dividends on common stock	(3,545)			(3,545)
Net income	32,488			32,488
Other (in shares)		(88,100)
Other	(25)	$ (10)	(15)
Other comprehensive loss	12,379				12,379
Ending Balance (in shares) at Jan. 31, 2018		41,714,903
Ending Balance at Jan. 31, 2018	$ 586,483	$ 4,624	180,083	459,462	1,246	(58,932)
Beginning Balance (in shares) at Jul. 31, 2018	41,706,084	41,706,084
Beginning Balance at Jul. 31, 2018	$ 608,867	$ 4,624	184,212	491,540	(11,456)	(60,053)
Increase (Decrease) in Stockholders' Equity
Repurchases of shares (in shares)		(37,802)
Repurchases of shares	(4,288)					(4,288)
Stock-based compensation	2,576		2,576
Equity vestings/option exercises (in shares)		53,320
Equity vestings/option exercises	955	$ 7	948
Cancellations of restricted stock (in shares)		(286)
Cancellations of restricted stock	0
Dividends on common stock	0			0
Net income	19,242			19,242
Other	(634)		(634)
Other comprehensive loss	(5,223)				(5,223)
Ending Balance (in shares) at Oct. 31, 2018		41,721,316
Ending Balance at Oct. 31, 2018	$ 622,360	$ 4,631	187,102	511,647	(16,679)	(64,341)
Beginning Balance (in shares) at Jul. 31, 2018	41,706,084	41,706,084
Beginning Balance at Jul. 31, 2018	$ 608,867	$ 4,624	184,212	491,540	(11,456)	(60,053)
Increase (Decrease) in Stockholders' Equity
Equity vestings/option exercises (in shares)	30,000
Net income	$ 38,042
Other comprehensive loss	$ (5,640)
Ending Balance (in shares) at Jan. 31, 2019	41,721,186	41,721,186
Ending Balance at Jan. 31, 2019	$ 641,603	$ 4,631	192,202	526,274	(17,096)	(64,408)
Beginning Balance (in shares) at Oct. 31, 2018		41,721,316
Beginning Balance at Oct. 31, 2018	622,360	$ 4,631	187,102	511,647	(16,679)	(64,341)
Increase (Decrease) in Stockholders' Equity
Repurchases of shares (in shares)		(880)
Repurchases of shares	(67)					(67)
Stock-based compensation	3,587		3,587
Equity vestings/option exercises (in shares)		1,857
Equity vestings/option exercises	0	$ 0	0
Cancellations of restricted stock (in shares)		(1,107)
Cancellations of restricted stock	0
Dividends on common stock	(4,173)			(4,173)
Net income	18,800			18,800
Other	1,513		1,513
Other comprehensive loss	$ (417)				(417)
Ending Balance (in shares) at Jan. 31, 2019	41,721,186	41,721,186
Ending Balance at Jan. 31, 2019	$ 641,603	$ 4,631	$ 192,202	$ 526,274	$ (17,096)	$ (64,408)

Condensed Consolidated Statem_4

Condensed Consolidated Statements of Cash Flows - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Cash flows from operating activities
Net income	$ 38,042	$ 55,417
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	9,563	8,190
Amortization	10,552	8,412
Stock-based compensation expense	6,163	4,590
Deferred income taxes	(3,096)	(6,453)
Other non-cash items, net	(154)	299
Changes in assets and liabilities, net of effects of acquisitions/dispositions:
Accounts receivable	(6,909)	1,145
Inventories	(9,517)	(8,073)
Prepaid expenses and other assets	(2,980)	(2,139)
Accounts payable and other liabilities	(10,105)	557
Income taxes	(2,365)	(7,274)
Net cash provided by operating activities	29,194	54,671
Cash flows from investing activities
Capital expenditures	(62,062)	(13,476)
Proceeds from sale of business	3,053	0
Acquisitions, net of cash acquired	(24,047)	(64,287)
Net cash used in investing activities	(83,056)	(77,763)
Cash flows from financing activities
Repayments of long-term debt	(5,000)	0
Borrowings under revolving credit facility	45,000	61,300
Repayments under revolving credit facility	0	(27,300)
Dividends paid	(4,173)	(3,545)
Purchases of treasury stock	(4,355)	(5,952)
Net cash provided by financing activities	31,472	24,503
Effect of exchange rate changes on cash and cash equivalents	(676)	1,982
(Decrease) increase in cash and cash equivalents	(23,066)	3,393
Cash and cash equivalents at beginning of period	94,097	36,584
Cash and cash equivalents at end of period	$ 71,031	$ 39,977

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jan. 31, 2019
Basis of Presentation
Basis of Presentation	Basis of Presentation Throughout this document, references to “Cantel,” “us,” “we,” “our,” and the “Company” are references to Cantel Medical Corp. and its subsidiaries, except where the context makes it clear the reference is to Cantel itself and not its subsidiaries. During the first quarter of fiscal 2019, we changed the names of our reportable segments to better align with our key customers and the markets we serve. This decision resulted in a change from a financial reporting perspective as the industrial biological and chemical indicator business has moved from the Dental segment to the Life Sciences segment. Prior year segment disclosures have been recast to conform to the current year presentation. See Note 15, “Reportable Segments.” Cantel is a leading provider of infection prevention products and services in the healthcare market, specializing in the following reportable segments: Medical, Life Sciences, Dental and Dialysis. Most of our equipment, consumables and supplies are used to help prevent the occurrence or spread of infections. The unaudited Condensed Consolidated Financial Statements have been prepared in accordance with United States generally accepted accounting principles for interim financial reporting and the requirements of Form 10-Q and Rule 10.01 of Regulation S-X. Accordingly, they do not include certain information and note disclosures required by generally accepted accounting principles for annual financial reporting and should be read in conjunction with the Consolidated Financial Statements and notes thereto included in the Annual Report of Cantel Medical Corp. on Form 10-K for the fiscal year ended July 31, 2018 (the “2018 Form 10-K”) and Management's Discussion and Analysis of Financial Condition and Results of Operations included elsewhere herein. The unaudited interim financial statements reflect all adjustments (of a normal and recurring nature) which management considers necessary for a fair presentation of the results of operations for these periods. The results of operations for the interim periods are not necessarily indicative of the results for the full year. The Condensed Consolidated Balance Sheet at July 31, 2018 was derived from the audited Consolidated Balance Sheet of Cantel at that date. Certain prior year amounts have been reclassified to conform to the current year presentation. Subsequent Events We performed a review of events subsequent to January 31, 2019 through the date of issuance of the accompanying unaudited consolidated interim financial statements.

Accounting Pronouncements

Accounting Pronouncements	6 Months Ended
	Jan. 31, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Accounting Pronouncements	Accounting Pronouncements Newly Adopted Accounting Standards In May 2017, the FASB issued ASU 2017-09, “ (Topic 718) Scope of Modification Accounting ,” (“ASU 2017-09”) to provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC 718. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017 (our fiscal year 2019), including interim periods within that reporting period. Accordingly, we adopted ASU 2017-09 on August 1, 2018. The adoption of ASU 2017-09 did not have a material impact on our financial position, results of operations and cash flows. In August 2016, the FASB issued ASU 2016-15, “(Topic 230) Classification of Certain Cash Receipts and Cash Payments , ” (“ASU 2016-15”). This guidance makes eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 (our fiscal year 2019). Accordingly, we adopted ASU 2016-15 on August 1, 2018. The adoption of ASU 2016-15 did not have a material impact on our financial position, results of operations and cash flows. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606) , ” (“ASU 2014-09”), which supersedes the revenue recognition requirements in Accounting Standards Codification 605, “Revenue Recognition” (“ASC 605”). ASU 2014-09 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606),” (“ASU 2015-14”), which defers the effective date of ASU 2014-09 by one year to fiscal years beginning after December 15, 2017 (our fiscal year 2019), including interim periods within that reporting period. In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606),” (“ASU 2016-12”), which provided narrow scope improvements and practical expedients relating to ASU 2014-09. We adopted the collective standard (“ASC 606”) on August 1, 2018. See Note 5, “Revenue Recognition” for a discussion of the impact and required disclosures. Recently Issued Accounting Standards In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (“ASU 2018-15”) to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 (our fiscal year 2021), including interim periods within that reporting period. The adoption of ASU 2018-15 is not expected to have a material impact on our financial position, results of operations or cash flows. In August 2018, the FASB issued ASU 2018-13, “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”) to modify the disclosure requirements on fair value measurements in ASC 820, “Fair Value Measurement” . ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 (our fiscal year 2021), including interim periods within that reporting period. The adoption of ASU 2018-13 is not expected to have a material impact on our financial position, results of operations or cash flows. In February 2018, the FASB issued ASU 2018-02, “Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” (“ASU 2018-02”) to allow for the reclassification from accumulated other comprehensive income to retained earnings of stranded tax effects resulting from the Tax Cuts and Jobs Act enacted in December 2017. ASU 2018-02 is effective for fiscal years beginning after December 15, 2018 (our fiscal year 2020), including interim periods within that reporting period. The adoption of ASU 2018-02 is not expected to have a material impact on our financial position, results of operations or cash flows. In August 2017, the FASB issued ASU 2017-12, “Targeted Improvements to Accounting for Hedging Activities” (“ASU 2017-12”) to improve the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. ASU 2017-12 is effective for fiscal years beginning after December 15, 2018 (our fiscal year 2020), including interim periods within that reporting period. The adoption of ASU 2017-12 is not expected to have a material impact on our financial position, results of operations or cash flows. In January 2017, the FASB issued ASU 2017-04, “(Topic 350) Simplifying the Test for Goodwill Impairment ,” (“ASU 2017-04”) to simplify the test for goodwill impairment. The revised guidance eliminates the existing Step 2 of the goodwill impairment test which required an entity to compute the implied fair value of its goodwill at the testing date in order to measure the amount of the impairment charge when the fair value of the reporting unit failed Step 1 of the goodwill impairment test. The guidance will be applied on a prospective basis on or after the effective date. ASU 2017-04 is effective for fiscal years beginning after December 31, 2019 (our fiscal year 2021) and early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of ASU 2017-04 is not expected to have a material impact on our financial position, results of operations or cash flows. In February 2016, the FASB issued ASU 2016-02, “ (Topic 842) Leases ,” (“ASU 2016-02”). The new guidance requires the recording of assets and liabilities arising from leases on the balance sheet accompanied by enhanced qualitative and quantitative disclosures in the notes to the financial statements. ASU 2016-02 is effective for fiscal years beginning after December 31, 2018 (our fiscal year 2020), including interim periods within that reporting period. Early adoption is permitted as of the beginning of an interim or annual period. In July 2018, the FASB issued ASU 2018-10, “Codification Improvements to Topic 842, Leases,” and ASU 2018-11, “Leases (Topic 842) Targeted Improvements,” and in December 2018, the FASB issued ASU 2018-20, “Narrow-Scope Improvements for Lessors.” These ASUs provide narrow adjustments relating to ASU 2016-02 and improvements to comparative reporting requirements for initial adoption and for separating components of a contract for lessors. We are currently in the process of evaluating the impact of the collective standard (“ASC 842”) on our financial position, results of operations and cash flows.

Acquisitions

Acquisitions	6 Months Ended
	Jan. 31, 2019
Business Combinations [Abstract]
Acquisitions	Acquisitions Fiscal 2019 Omnia: On February 1, 2019, we purchased all of the issued and outstanding stock of Omnia S.p.A. (“Omnia”), an Italian-based market leader in dental surgical consumables solutions, for total consideration (net of cash acquired), excluding acquisition-related costs, of $27,190 , consisting of $23,971 of cash and $3,219 of stock consideration, plus contingent consideration ranging from zero to a maximum of $5,800 , which is payable upon the achievement of certain performance-based financial targets. Omnia’s business consists of a wide-ranging portfolio of sutures, irrigation tubing and customized dental surgical procedure kits, with a focus on procedure room set-up and cross-contamination prevention. Omnia will be included in our Dental segment. CES business: On August 1, 2018, we acquired certain net assets of Stericycle Inc. related to its controlled environmental solutions business (“CES business”) for total cash consideration, excluding acquisition-related costs, of $17,047 . The CES business is a leading provider of testing and certification, environmental monitoring and decontamination services for clean rooms and other controlled environments to ensure safety, regulatory compliance and quality control, and is included in our Life Sciences segment. Fiscal 2018 Aexis: On March 21, 2018, we purchased all of the issued and outstanding stock of Aexis Medical BVBA (“Aexis”) for total consideration, excluding acquisition-related costs, of $21,600 , consisting of $20,308 of cash consideration (net of cash acquired), plus contingent consideration ranging from zero to a maximum of $1,850 , which is payable upon the achievement of certain purchase order targets through March 21, 2020. Aexis specializes in advanced software solutions focused on the tracking and monitoring of instrument reprocessing for hospitals and healthcare professionals, and is included in our Medical segment. BHT Group: On August 23, 2017, we purchased all of the issued and outstanding stock of BHT Hygienetechnik Holding GmbH (“BHT Group”), a leader in the German market in automated endoscope reprocessing and related equipment and services for total consideration (net of cash acquired), excluding acquisition related costs, of $60,216 . BHT Group consists of a portfolio of high-quality automatic endoscope reprocessors, advanced endoscope storage and drying cabinets (products globally distributed by our Company prior to the acquisition under an agreement with BHT Group), washer-disinfectors for central sterile applications, associated technical service and parts as well as flexible endoscope repair services. BHT Group is included in our Medical segment. The following table presents our purchase price allocations of our material acquisitions: 2019 2018 Purchase Price Allocation CES Business (1) Aexis (1) BHT Group (1) (Preliminary) (Preliminary) (Final) Purchase Price: Cash paid $ 17,047 $ 20,308 $ 60,216 Fair value of contingent consideration — 1,292 — Total $ 17,047 $ 21,600 $ 60,216 Allocation: Property and equipment 539 130 835 Amortizable intangible assets: Customer relationships 8,100 1,800 12,500 Technology — 4,600 6,200 Goodwill 6,137 17,092 40,934 Deferred income taxes — (1,639 ) (5,881 ) Other working capital 2,271 909 5,628 Contingent consideration — (1,292 ) — Total $ 17,047 $ 21,600 $ 60,216 _______________________________________________ (1) The excess purchase price over net assets acquired was assigned to goodwill, all of which is deductible for income tax purposes. Unaudited Pro Forma Summary of Operations The acquisitions above, both individually and in the aggregate, were not material to our consolidated results of operations or financial position and, therefore, pro forma financial information is not presented.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jan. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Stock-Based Compensation	Stock-Based Compensation 2016 Equity Incentive Plan At January 31, 2019 , 275,400 nonvested restricted stock awards were outstanding under the 2016 plan. No options were outstanding under the 2016 plan. At January 31, 2019 , 815,698 shares were collectively available for issuance pursuant to restricted stock and other stock awards, stock options and stock appreciation rights. 2006 Equity Incentive Plan The 2006 Plan was terminated on January 7, 2016 in conjunction with the adoption of the 2016 Plan. At January 31, 2019 , options to purchase 40,000 shares of common stock were outstanding under the 2006 Plan. No additional awards will be granted under this plan. The following table shows the components of stock-based compensation expense recognized in the condensed consolidated statements of income: Three Months Ended January 31, Six Months Ended January 31, 2019 2018 2019 2018 Cost of sales $ 287 $ 181 $ 524 $ 296 Operating expenses: Selling 575 264 1,146 629 General and administrative 2,665 2,257 4,375 3,590 Research and development 60 37 118 75 Total operating expenses 3,300 2,558 5,639 4,294 Stock-based compensation expense $ 3,587 $ 2,739 $ 6,163 $ 4,590 At January 31, 2019 , total unrecognized stock-based compensation expense related to total nonvested stock options and restricted stock awards was $19,881 with a remaining weighted average period of 19 months over which such expense is expected to be recognized. We determined the fair value of our market-based restricted stock awards using a Monte Carlo simulation on the date of grant using the following assumptions: Six Months Ended January 31, 2019 2018 Volatility of common stock 27.54 % 26.60 % Average volatility of peer companies 36.55 % 33.72 % Average correlation coefficient of peer companies 27.18 % 32.26 % Risk-free interest rate 2.93 % 1.62 % A summary of nonvested stock award activity for the six months ended January 31, 2019 follows: Number of Time-based Awards Number of Performance-based Awards Number of Market-based Awards Number of Total Awards Weighted Average Fair Value July 31, 2018 168,320 26,076 17,710 212,106 $ 88.87 Granted 122,478 27,231 16,765 166,474 $ 91.63 Vested (1) (85,308 ) (10,284 ) — (95,592 ) $ 76.71 Forfeited (6,865 ) (723 ) — (7,588 ) $ 89.13 January 31, 2019 198,625 42,300 34,475 275,400 $ 94.99 _______________________________________________ (1) The aggregate fair value of all nonvested stock awards which vested was approximately $7,335 . A summary of stock option activity for the six months ended January 31, 2019 follows: Number of shares Weighted Average Exercise Price Weighted Average Contractual Life Remaining (Years) Aggregate Intrinsic Value Outstanding at July 31, 2018 70,000 $ 38.60 Exercised (30,000 ) $ 31.81 Outstanding at January 31, 2019 40,000 $ 43.70 1.07 $ 1,509 Exercisable at January 31, 2019 40,000 $ 43.70 1.07 $ 1,509 During the six months ended January 31, 2019 , 5,000 options vested, with an aggregate fair value of approximately $277 . During the six months ended January 31, 2019 , 30,000 options were exercised, with an aggregate fair value of approximately $1,787 . At January 31, 2019 , all outstanding options were vested. Excess tax benefits arise when the ultimate tax effect of the deduction for tax purposes is greater than the income tax benefit on stock-based compensation. For the six months ended January 31, 2019 , income tax deductions of $3,059 were generated, of which $2,062 were recorded as a reduction in income tax expense over the equity awards’ vesting period and the remaining excess tax benefit of $997 was recorded as a reduction in income tax expense. For the six months ended January 31, 2018 , income tax deductions of $3,406 were generated, of which $1,394 were recorded as a reduction in income tax expense over the equity awards’ vesting period and the remaining excess tax benefit of $2,012 was recorded as a reduction in income tax expense.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jan. 31, 2019
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Adoption of “Revenue from Contracts with Customers (ASC 606)” We adopted ASC 606, effective August 1, 2018, using the modified retrospective method applied to those contracts which were not completed as of August 1, 2018. Results for reporting beginning after August 1, 2018 are presented under ASC 606, while prior period amounts are not adjusted and will continue to be reported in accordance with our historic accounting under ASC 605. Due to the cumulative impact of adopting ASC 606, we recorded a net increase of $865 to opening retained earnings, net of tax, as of August 1, 2018. The impact is primarily related to the timing of revenue recognition for the shipment of products in both our Medical and Life Sciences segments where risk of loss provisions are present (“synthetic FOB destination”). The new standard does not require us to defer revenue for these products and allows us to recognize revenue at the time of shipment. The cumulative adjustment to retained earnings also includes the impact of the change in timing of revenue recognition associated with software licensing arrangements in our Medical segment. Additionally, revenue related to software renewals was historically recognized on a ratable basis over the license period. Under ASC 606, the license is considered functional intellectual property, and is considered to be transferred to the customer at a point in time, specifically, at the start of each annual renewal period. As a result, revenue related to our annual software license renewals has been accelerated. Revenue Recognition A portion of our medical, life sciences and dialysis sales include multiple performance obligations, whereby revenue is allocated to the equipment, installation and consumable components based upon their relative standalone selling prices, which includes comparable historical transactions of similar equipment, installation and consumables sold as stand-alone components. Revenue on capital equipment and consumables is recognized when control of the equipment or consumable transfers to the customer, which is generally driven by the underlying shipping terms of the transaction. Revenue on the installation component is recognized when the installation is complete. The most significant judgments related to these arrangements include identifying the various performance obligations of these arrangements and determining the relative standalone selling price of each performance obligation. With respect to certain of our customers, rebates are provided. Such rebates, which consist primarily of volume rebates, are provided for as a reduction of sales at the time of revenue recognition. Such allowances are determined based on estimated projections of sales volume for the entire rebate periods. If it becomes known that sales volume to customers will deviate from original projections, the rebate provisions originally established would be adjusted accordingly. We also offer certain volume-based rebates to our distribution customers, which we record as variable consideration when calculating the transaction price. We use information available at the time and our historical experience with each customer to estimate the rebate amount by applying the expected value method. The following table gives information as to the net sales disaggregated by geography and product line: Three Months Ended January 31, Six Months Ended January 31, Net sales by geography 2019 2018 2019 2018 (1) United States $ 165,164 $ 157,708 $ 334,102 $ 318,648 Europe/Africa/Middle East 34,319 32,498 66,333 60,553 Asia/Pacific 15,568 12,987 31,320 26,849 Canada 8,138 8,318 15,509 16,796 Latin America/South America 1,349 1,523 2,863 2,954 Total $ 224,538 $ 213,034 $ 450,127 $ 425,800 Net sales by product line Capital equipment $ 57,387 $ 59,071 $ 115,519 $ 118,240 Consumables 135,731 127,413 272,552 255,807 Product service 30,525 26,550 60,354 51,351 All other (2) 895 — 1,702 402 Total $ 224,538 $ 213,034 $ 450,127 $ 425,800 _______________________________________________ (1) As noted above, prior year amounts have not been adjusted under the modified retrospective method. (2) Primarily includes software licensing revenues. Remaining Performance Obligations At January 31, 2019 , the estimated revenue expected to be recognized in the future related to performance obligations that are unsatisfied (or partially unsatisfied) was approximately $67,281 , primarily within the Medical segment. We expect to recognize revenue on approximately 65% of these remaining performance obligations over the remainder of fiscal 2019 and fiscal 2020. These performance obligations primarily reflect the future product service revenues for multi-period service arrangements. Contract Liabilities Contract liabilities primarily relate to payments received from customers in advance of performance under the contract. Our contract liabilities arise primarily in the Medical and Life Sciences segments when payment is received upfront for various multi-period extended service arrangements. We expect to recognize substantially all of this revenue over the next twelve months. A summary of contract liabilities activity for the six months ended January 31, 2019 follows: Contract Liabilities Balance, August 1, 2018 $ 29,015 Revenue deferred in current year 31,525 Deferred revenue recognized (32,444 ) Foreign currency translation (443 ) Balance, January 31, 2019 27,653 Contract liabilities included in Other long-term liabilities (517 ) Deferred revenue $ 27,136 Practical Expedients and Policy Elections As part of the cost to obtain a contract, we may pay incremental commissions to sales employees upon entering into a sales contract. Under ASC 606, we have elected to expense these costs as incurred when the period of benefit is less than one year. For certain multi-period contracts, we capitalize these amounts as contract costs, and amortize them based on the contract duration to which the assets relate, which ranges from two to five years. The amounts at January 31, 2019 , were not material. For certain international contracts with distributors, we recognize a receivable at the point in time in which we have an unconditional right to payment. Most customers are required to pay a portion of the transaction price in advance and the remaining balance within 30 days of receiving the related products. Accordingly, we have elected to use the practical expedient which allows us to ignore the possible existence of a significant financing component within these contracts. As a policy, for shipping and handling costs incurred after the customer has obtained control of a good, we will continue to treat these costs as a fulfillment cost rather than as an additional promised service. Additionally, in certain U.S. states, we are required to collect sales taxes from our customers, and in certain international jurisdictions, we are required to collect value added taxes. The tax collected is recorded as a liability until remitted to the taxing authority.

Inventories, Net

Inventories, Net	6 Months Ended
	Jan. 31, 2019
Inventory Disclosure [Abstract]
Inventories, Net	Inventories, Net A summary of inventories is as follows: January 31, 2019 July 31, 2018 Raw materials and parts $ 57,812 $ 49,054 Work-in-process 11,573 13,189 Finished goods 55,738 53,948 Reserve for excess and obsolete inventory (9,237 ) (8,599 ) Total $ 115,886 $ 107,592

Derivatives

Derivatives	6 Months Ended
	Jan. 31, 2019
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Derivatives	Derivatives In order to hedge against the impact of fluctuations in the value of the Euro, British Pound, Canadian dollar, Australian dollar and Singapore dollar relative to the U.S. dollar on the conversion of such net assets into the functional currencies, we enter into short-term forward contracts to purchase Euros, British Pounds, Canadian dollars, Australian dollars and Singapore dollars, which contracts are one-month in duration. These short-term contracts are designated as fair value hedge instruments. These foreign currency forward contracts are continually replaced with new one -month contracts as long as we have significant net assets that are denominated and ultimately settled in currencies other than each entity’s functional currency. Gains and losses related to hedging contracts to buy Euros, British Pounds, Canadian dollars, Australian dollars and Singapore dollars forward are immediately realized within general and administrative expenses due to the short-term nature of such contracts. We do not currently hedge against the impact of fluctuations in the value of the Chinese Renminbi and Sri Lankan Rupee relative to the U.S. dollar because the overall foreign currency exposure relating to these currencies is not material. There were seven foreign currency forward contracts with an aggregate notional value of $62,904 and $30,159 at January 31, 2019 and July 31, 2018 , respectively, which covered certain assets and liabilities that were denominated in currencies other than each entity’s functional currency. For the six months ended January 31, 2019 and 2018 , the settlements of our forward contracts resulted in immaterial amounts of currency conversion gains and losses on the hedged items in the aggregate.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jan. 31, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements Fair Value Hierarchy We apply the provisions of ASC 820, “Fair Value Measurements and Disclosures,” (“ASC 820”), for our financial assets and liabilities that are re-measured and reported at fair value each reporting period and our nonfinancial assets and liabilities that are re-measured and reported at fair value on a non-recurring basis. We define fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis Our financial assets that are re-measured at fair value on a recurring basis include money market funds that are classified as cash and cash equivalents in the consolidated balance sheets. These money market funds are classified within Level 1 of the fair value hierarchy and are valued using quoted market prices for identical assets. For the Aexis acquisition, additional purchase price payments ranging from zero to $1,850 are contingent upon the achievement of certain purchase order targets through March 21, 2020. We estimated the original fair value of the contingent consideration using the weighted probabilities of the possible contingent payments. At the date of acquisition, we estimated the original fair value of the contingent consideration to be $1,292 . We are required to reassess the fair value of contingent payments on a periodic basis. The significant inputs used in these estimates include numerous possible scenarios for the payments based on the contractual terms of the contingent consideration, for which probabilities are assigned to each scenario. Given the short term nature of the financial instrument, the contingent consideration is not discounted to present value. Although we believe our assumptions are reasonable, different assumptions or changes in the future may result in different estimated amounts. In connection with the Jet Prep Ltd. (“Jet Prep”) acquisition in fiscal 2014, we assumed a contingent obligation payable to the Israeli Government based on future sales. This fair value measurement was based on significant inputs not observed in the market and thus represent Level 3 measurements. In November 2017, the Israeli Government formally notified us that they would forgive any future amounts payable due to our decision to exit the Jet Prep business. During the first quarter of fiscal 2018, we reduced the fair value of this obligation to zero. See Note 11, “Commitments and Contingencies.” The fair values of our financial instruments measured on a recurring basis were categorized as follows: January 31, 2019 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Money markets $ 104 $ — $ — $ 104 Total assets $ 104 $ — $ — $ 104 Liabilities: Other long-term liabilities: Contingent consideration — — 1,352 1,352 Total liabilities $ — $ — $ 1,352 $ 1,352 July 31, 2018 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Money markets $ 104 $ — $ — $ 104 Total assets $ 104 $ — $ — $ 104 Liabilities: Other long-term liabilities: Contingent obligation — — 1,298 1,298 Total liabilities $ — $ — $ 1,298 $ 1,298 A reconciliation of our liabilities that are measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows: Aexis Contingent Consideration Balance, July 31, 2018 $ 1,298 Net activity 54 Balance, January 31, 2019 $ 1,352 Disclosure of Fair Value of Financial Instruments At January 31, 2019 and July 31, 2018 , the carrying amounts for cash and cash equivalents (excluding money markets), accounts receivable and accounts payable approximated fair value due to the short maturity of these instruments. At January 31, 2019 and July 31, 2018 , the carrying value of our outstanding borrowings under our credit facility approximated the fair value of these obligations as the respective borrowings rates reflect prevailing market interest rates.

Intangibles and Goodwill

Intangibles and Goodwill	6 Months Ended
	Jan. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Intangibles and Goodwill	Intangibles and Goodwill Our intangible assets consist of the following: January 31, 2019 July 31, 2018 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Intangible assets with finite lives: Customer relationships (1) $ 135,330 $ (46,153 ) $ 89,177 $ 133,347 $ (45,618 ) $ 87,729 Technology (1) 58,728 (20,144 ) 38,584 54,585 (19,836 ) 34,749 Brand names (1) 6,919 (2,944 ) 3,975 8,141 (3,857 ) 4,284 Non-compete agreements (1) 2,880 (1,555 ) 1,325 3,060 (1,628 ) 1,432 Patents and other registrations 2,987 (1,195 ) 1,792 2,826 (1,179 ) 1,647 206,844 (71,991 ) 134,853 201,959 (72,118 ) 129,841 Trademarks and tradenames 6,695 — 6,695 7,520 — 7,520 Total intangible assets $ 213,539 $ (71,991 ) $ 141,548 $ 209,479 $ (72,118 ) $ 137,361 _______________________________________________ (1) During the six months ended January 31, 2019 , we wrote off $10,319 of fully amortized intangible assets. Amortization expense related to intangible assets was $10,552 and $8,412 for the six months ended January 31, 2019 and 2018 , respectively. We expect to recognize an additional $9,611 of amortization expense related to intangible assets for the remainder of fiscal 2019 , and thereafter $17,384 , $17,077 , $16,695 , $15,665 and $14,786 of amortization expense for fiscal years 2020 , 2021 , 2022 , 2023 and 2024 , respectively. Goodwill changed during the six months ended January 31, 2019 as follows: Medical Life Sciences Dental Dialysis Total Goodwill Balance, July 31, 2018 $ 186,690 $ 58,925 $ 114,279 $ 8,133 $ 368,027 Acquisitions — 6,137 — — 6,137 Divestitures — (495 ) — — (495 ) Foreign currency translation (2,562 ) (92 ) — — (2,654 ) Balance, January 31, 2019 $ 184,128 $ 64,475 $ 114,279 $ 8,133 $ 371,015

Financing Arrangements

Financing Arrangements	6 Months Ended
	Jan. 31, 2019
Debt Disclosure [Abstract]
Financing Arrangements	Financing Arrangements Our long-term debt consists of the following: January 31, 2019 July 31, 2018 Revolving credit loans outstanding $ 45,000 $ — Tranche A term loan outstanding 195,000 200,000 Unamortized debt issuance costs (2,423 ) (2,698 ) Total long-term debt, net of unamortized debt issuance costs 237,577 197,302 Current portion of long-term debt (10,000 ) (10,000 ) Long-term debt, net of unamortized debt issuance costs and excluding current portion $ 227,577 $ 187,302 On June 28, 2018, we entered into a Fourth Amended and Restated Credit Agreement (the “2018 Credit Agreement”). The 2018 Agreement refinances our credit facility under the Third Amended and Restated Credit Agreement (the “Existing Credit Agreement”) dated March 4, 2014, to include a $200,000 tranche A term loan and a $400,000 revolving credit facility. Subject to the satisfaction of certain conditions precedent, including the consent of the lenders, we may from time to time increase our borrowing capacity under the revolving credit facility or tranche A term loan by an aggregate amount not to exceed $300,000 . The 2018 Credit Agreement expires on June 28, 2023. Additionally, subject to certain restrictions and conditions (i) any of our domestic or foreign subsidiaries may become borrowers and (ii) borrowings may occur in multi-currencies. At January 31, 2019 , we had $195,000 of term loan A borrowings outstanding and $45,000 revolver borrowings under the 2018 Credit Agreement. The tranche A term loan is subject to principal amortization, with $10,000 due and payable in each of fiscal 2019, 2020, 2021 and 2022, with the remaining $160,000 due and payable at maturity on June 28, 2023. During the six months ended January 31, 2019 , we made principal payments of $5,000 . Borrowings under the 2018 Credit Agreement bear interest at rates ranging from 0.00% to 1.00% above prime rate for base rate borrowings, or at rates ranging from 1.00% to 2.00% above the London Interbank Offered Rate (“LIBOR”), depending upon our “Consolidated Leverage Ratio,” which is defined as the consolidated ratio of total funded debt to earnings before interest, taxes, depreciation and amortization, and as further adjusted under the terms of the 2018 Credit Agreement (“Consolidated EBITDA”). At January 31, 2019 , the lender’s base rate was 5.75% and the LIBOR rate was 3.77% . The margins applicable to our outstanding borrowings were 0.25% above the lender’s base rate or 1.25% above LIBOR. All of our outstanding borrowings were under LIBOR contracts at January 31, 2019 . The 2018 Credit Agreement also provides for fees on the unused portion of our facility at rates ranging from 0.20% to 0.35% , depending upon our Consolidated Leverage Ratio, which was 0.20% at January 31, 2019 . At January 31, 2019 , the interest rate on our outstanding borrowings was approximately 3.75% . The 2018 Credit Agreement contains affirmative and negative covenants reasonably customary for similar credit facilities and is secured by (i) substantially all assets of Cantel and its U.S.-based subsidiaries, (ii) a pledge by Cantel of all of the outstanding shares of its U.S.-based subsidiaries and 65% of the outstanding shares of certain of Cantel’s foreign-based subsidiaries and (iii) a guaranty by Cantel’s domestic subsidiaries. We are in compliance with all financial covenants under the 2018 Credit Agreement.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jan. 31, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Contingent Consideration and Assumed Contingent Liability At January 31, 2019 , $1,352 was recorded related to the Aexis acquisition, which is for the estimated fair value of contingent consideration payable upon the achievement of certain purchase order targets through March 21, 2020. During fiscal 2017, we decided to exit the Jet Prep business that was acquired in fiscal 2014. At the time of the acquisition, we assumed a contingent obligation payable to the Israeli Government based on future sales. In November 2017, the Israeli Government formally notified us that they would forgive any future amounts payable due to our decision to exit the Jet Prep business. As a result of this formal notification, we reduced the $1,138 contingent obligation to zero during the first quarter of fiscal 2018, resulting in a benefit through other income for the six months ended January 31, 2018 . Legal Matters In the normal course of business, we are subject to pending and threatened legal actions. It is our policy to accrue for amounts related to these legal matters if it is probable that a liability has been incurred and an amount of anticipated exposure can be reasonably estimated. We do not believe that any of these pending claims or legal actions will have a material effect on our business, financial condition, results of operations or cash flows.

Earnings Per Common Share

Earnings Per Common Share	6 Months Ended
	Jan. 31, 2019
Earnings Per Share [Abstract]
Earnings Per Common Share	Earnings Per Common Share Basic EPS is computed based upon the weighted average number of common shares outstanding for the year. Diluted EPS is computed based upon the weighted average number of common shares outstanding for the year plus the dilutive effect of common stock equivalents using the treasury stock method and the average market price of our common stock for the year. We include participating securities (nonvested share-based payment awards that contain non-forfeitable rights to dividends or dividend equivalents) in the computation of EPS pursuant to the two-class method. Our participating securities consist solely of nonvested restricted stock awards, which have contractual participation rights equivalent to those of stockholders of unrestricted common stock. The two-class method of computing earnings per share is an allocation method that calculates earnings per share for common stock and participating securities. The following table sets forth the computation of basic and diluted EPS available to stockholders of common stock (excluding participating securities): Three Months Ended January 31, Six Months Ended January 31, 2019 2018 2019 2018 Numerator for basic and diluted earnings per share: Net income $ 18,800 $ 32,488 $ 38,042 $ 55,417 Less income allocated to participating securities (16 ) (107 ) (49 ) (225 ) Net income available to common shareholders $ 18,784 $ 32,381 $ 37,993 $ 55,192 Denominator for basic and diluted earnings per share, adjusted for participating securities: Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock 41,667,955 41,578,483 41,660,095 41,549,570 Dilutive effect of stock awards using the treasury stock method and the average market price for the year 18,088 55,561 41,558 60,897 Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock 41,686,043 41,634,044 41,701,653 41,610,467 Earnings per share attributable to common stock: Basic earnings per share $ 0.45 $ 0.78 $ 0.91 $ 1.33 Diluted earnings per share $ 0.45 $ 0.78 $ 0.91 $ 1.33 Stock options excluded from weighted average dilutive common shares because their inclusion would have been anti-dilutive — — — — A reconciliation of weighted average number of shares and common stock equivalents attributable to common stock, as determined above, to our total weighted average number of shares and common stock equivalents, including participating securities, is set forth in the following table: Three Months Ended January 31, Six Months Ended January 31, 2019 2018 2019 2018 Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock 41,686,043 41,634,044 41,701,653 41,610,467 Participating securities 33,400 138,508 55,436 172,205 Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities 41,719,443 41,772,552 41,757,089 41,782,672

Income Taxes

Income Taxes	6 Months Ended
	Jan. 31, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes On December 22, 2017, the U.S. government enacted wide-ranging tax legislation, the Tax Cuts and Jobs Act (the “2017 Tax Act”). The 2017 Tax Act significantly revised U.S. tax law by, among other provisions, (a) lowering the applicable U.S. federal statutory income tax rate from 35% to 21%, (b) creating a partial territorial tax system that includes imposing a mandatory one-time transition tax on previously deferred foreign earnings, (c) creating provisions regarding the (1) Global Intangible Low Tax Income (“GILTI”), (2) the Foreign Derived Intangible Income (“FDII”) deduction, and (3) the Base Erosion Anti-Abuse Tax (“BEAT”), and (d) eliminating or reducing certain income tax deductions, such as interest expense, executive compensation expenses and certain employee expenses. ASC 740, “ Income Taxes, ” requires the effects of changes in tax laws to be recognized in the period in which the legislation is enacted. However, due to the complexity and significance of the 2017 Tax Act’s provisions, the SEC staff issued Staff Accounting Bulletin No. 118 (“SAB 118”), which allows companies to record the tax effects of the 2017 Tax Act on a provisional basis and then, if necessary, subsequently adjust such amounts during a limited measurement period as more information becomes available. The measurement period ends when a company has obtained, prepared, and analyzed the information necessary to finalize its accounting, but cannot extend beyond one year from enactment. As a result, we provided a provisional estimate of the effect of the Tax Act for the fiscal year ended July 31, 2018, and recorded a net benefit of $8,657 due to the impact on our deferred taxes on the basis of the actual fiscal 2018 results of operations. The measurement period provided by SAB 118 concluded during the second quarter of fiscal 2019, and no material adjustments were made to the provisional estimates recorded. As part of U.S. tax reform, the 2017 Tax Act imposed a one-time transition tax on certain accumulated positive foreign earnings (net of foreign deficits) across all non-U.S. subsidiaries, as computed under U.S. tax principles. As of December 31, 2017, our non-U.S. subsidiaries were in a net foreign deficit position in the aggregate, and therefore no accrual for the transition tax was made. Section 15 of the Internal Revenue Code (the “Code”) governs rate changes and was not amended by the 2017 Tax Act. Section 15 requires a blended tax rate for fiscal-year taxpayers for their fiscal year that includes the effective date of the rate change, which was January 1, 2018. As a result of the 2017 Tax Act, we revised our estimated annual effective rate to reflect the change in the U.S. federal statutory rate by computing a tentative tax under both rates, and then prorating the tentative tax based on the number of days with and without the rate change to arrive at a blended tax rate of 26.9% , as required by the Code. This blended rate was applied for fiscal 2018 (beginning with the second quarter) and the new U.S. federal statutory rate of 21% applies to fiscal 2019 and beyond. As noted above, the 2017 Tax Act also establishes new tax laws that will affect the fiscal year ending July 31, 2019, which include the GILTI provision, the FDII deduction, a new minimum tax related to payments to foreign subsidiaries and affiliates known as BEAT and certain employee expense deductions. The provisional estimates were based on our understanding of the 2017 Tax Act and other information available at the time of the estimates, including assumptions and expectations about future events, such as projected financial performance, and are subject to further refinement as additional information becomes available, including potential new or interpretative guidance issued by the SEC, the FASB, or IRS. A reconciliation of the consolidated effective income tax rate is as follows: Three Months Ended Six Months Ended Effective Rate, January 31, 2018 (3.6 )% 11.9 % Deferred tax revaluation 27.5 % 13.7 % U.S. federal statutory rate decrease (5.8 )% (5.8 )% Prior quarter true-up due to U.S. federal statutory rate decrease 8.2 % — % Foreign operations (1.8 )% 1.6 % State taxes 0.1 % 0.5 % Excess tax benefit (0.9 )% 1.2 % Other 2.0 % 2.2 % Effective Rate, January 31, 2019 25.7 % 25.3 %

Accumulated Other Comprehensive

Accumulated Other Comprehensive Loss	6 Months Ended
	Jan. 31, 2019
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Loss	Accumulated Other Comprehensive Loss The components and changes in accumulated other comprehensive loss were as follows: Three Months Ended January 31, Six Months Ended January 31, 2019 2018 2019 2018 Beginning balance $ (16,679 ) $ (11,133 ) $ (11,456 ) $ (9,900 ) Other comprehensive (income) loss due to foreign currency translation (417 ) 12,379 (5,640 ) 11,146 Ending balance $ (17,096 ) $ 1,246 $ (17,096 ) $ 1,246

Reportable Segments

Reportable Segments	6 Months Ended
	Jan. 31, 2019
Segment Reporting [Abstract]
Reportable Segments	Reportable Segments In accordance with ASC Topic 280, “ Segment Reporting,” (“ASC 280”), we have determined our reportable business segments based upon an assessment of product types, organizational structure, customers and internally prepared financial statements. The primary factors used by us in analyzing segment performance are net sales and income from operations. During the first quarter of fiscal 2019, we changed the names of our reportable segments to better align with our key customers and the markets we serve. As a result of this change, our industrial biological and chemical indicator business has moved from the Dental segment to the Life Sciences segment. Prior year segment disclosures have been recast to conform to the current year presentation. Our reportable segments are as follows: Medical: designs, develops, manufactures, sells and installs a comprehensive offering of products and services comprising a complete circle of infection prevention solutions. Our products include endoscope reprocessing and endoscopy procedure products. Life Sciences: designs, develops, manufactures, sells, and installs water purification systems for medical, pharmaceutical and other bacteria controlled applications. We also provide filtration/separation and disinfectant technologies to the medical and life science markets through a worldwide distributor network. Two customers collectively accounted for approximately 42.5% and 51.3% of our Life Sciences segment net sales for the six months ended January 31, 2019 and 2018 , respectively. Dental: designs, manufactures, sells, supplies and distributes a broad selection of infection prevention healthcare products, the majority of which are single-use products used by dental practitioners. Three customers collectively accounted for approximately 47.9% and 48.3% of our Dental segment net sales for the six months ended January 31, 2019 and 2018 , respectively. Dialysis: designs, develops, manufactures, sells and services reprocessing systems and sterilants for dialyzers (a device serving as an artificial kidney), as well as dialysate concentrates and supplies utilized for renal dialysis. Two customers accounted for approximately 20.6% and 38.7% of our Dialysis segment net sales for the six months ended January 31, 2019 and 2018 , respectively. These customers are the same two customers noted above under our Life Sciences segment. None of our customers accounted for 10% or more of our consolidated net sales for the six months ended January 31, 2019 and 2018 . Information as to reportable segments is summarized below: Three Months Ended January 31, Six Months Ended January 31, Net sales 2019 2018 2019 2018 Medical $ 128,580 $ 116,665 $ 256,132 $ 229,050 Life Sciences 51,869 52,337 105,214 107,107 Dental 35,933 36,090 72,561 73,767 Dialysis 8,156 7,942 16,220 15,876 Total net sales $ 224,538 $ 213,034 $ 450,127 $ 425,800 Three Months Ended January 31, Six Months Ended January 31, Income from operations 2019 2018 2019 2018 Medical $ 25,525 $ 24,463 $ 50,736 $ 44,147 Life Sciences 7,323 8,583 13,654 18,958 Dental 4,888 6,558 10,813 15,233 Dialysis 1,193 1,918 2,577 4,017 38,929 41,522 77,780 82,355 General corporate expenses 12,733 9,040 23,906 18,239 Total income from operations $ 26,196 $ 32,482 $ 53,874 $ 64,116

Accounting Pronouncements (Poli

Accounting Pronouncements (Policies)	6 Months Ended
	Jan. 31, 2019
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Newly Adopted And Recently Issued Accounting Standards	Newly Adopted Accounting Standards In May 2017, the FASB issued ASU 2017-09, “ (Topic 718) Scope of Modification Accounting ,” (“ASU 2017-09”) to provide guidance about which changes to the terms or conditions of a share-based payment award require an entity to apply modification accounting in ASC 718. ASU 2017-09 is effective for fiscal years beginning after December 15, 2017 (our fiscal year 2019), including interim periods within that reporting period. Accordingly, we adopted ASU 2017-09 on August 1, 2018. The adoption of ASU 2017-09 did not have a material impact on our financial position, results of operations and cash flows. In August 2016, the FASB issued ASU 2016-15, “(Topic 230) Classification of Certain Cash Receipts and Cash Payments , ” (“ASU 2016-15”). This guidance makes eight targeted changes to how cash receipts and cash payments are presented and classified in the statement of cash flows. ASU 2016-15 is effective for fiscal years beginning after December 15, 2017 (our fiscal year 2019). Accordingly, we adopted ASU 2016-15 on August 1, 2018. The adoption of ASU 2016-15 did not have a material impact on our financial position, results of operations and cash flows. In May 2014, the FASB issued ASU 2014-09, “Revenue from Contracts with Customers (Topic 606) , ” (“ASU 2014-09”), which supersedes the revenue recognition requirements in Accounting Standards Codification 605, “Revenue Recognition” (“ASC 605”). ASU 2014-09 is based on the principle that revenue is recognized to depict the transfer of goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. It also requires additional disclosure about the nature, amount, timing and uncertainty of revenue and cash flows arising from customer contracts, significant judgments and changes in judgments, and assets recognized from costs incurred to obtain or fulfill a contract. In August 2015, the FASB issued ASU 2015-14, “Revenue from Contracts with Customers (Topic 606),” (“ASU 2015-14”), which defers the effective date of ASU 2014-09 by one year to fiscal years beginning after December 15, 2017 (our fiscal year 2019), including interim periods within that reporting period. In May 2016, the FASB issued ASU 2016-12, “Revenue from Contracts with Customers (Topic 606),” (“ASU 2016-12”), which provided narrow scope improvements and practical expedients relating to ASU 2014-09. We adopted the collective standard (“ASC 606”) on August 1, 2018. See Note 5, “Revenue Recognition” for a discussion of the impact and required disclosures. Recently Issued Accounting Standards In August 2018, the FASB issued ASU 2018-15, “Customer’s Accounting for Implementation Costs Incurred in a Cloud Computing Arrangement That Is a Service Contract” (“ASU 2018-15”) to help entities evaluate the accounting for fees paid by a customer in a cloud computing arrangement (hosting arrangement) by providing guidance for determining when the arrangement includes a software license. ASU 2018-15 is effective for fiscal years beginning after December 15, 2019 (our fiscal year 2021), including interim periods within that reporting period. The adoption of ASU 2018-15 is not expected to have a material impact on our financial position, results of operations or cash flows. In August 2018, the FASB issued ASU 2018-13, “Disclosure Framework—Changes to the Disclosure Requirements for Fair Value Measurement” (“ASU 2018-13”) to modify the disclosure requirements on fair value measurements in ASC 820, “Fair Value Measurement” . ASU 2018-13 is effective for fiscal years beginning after December 15, 2019 (our fiscal year 2021), including interim periods within that reporting period. The adoption of ASU 2018-13 is not expected to have a material impact on our financial position, results of operations or cash flows. In February 2018, the FASB issued ASU 2018-02, “Reclassification of Certain Tax Effects from Accumulated Other Comprehensive Income” (“ASU 2018-02”) to allow for the reclassification from accumulated other comprehensive income to retained earnings of stranded tax effects resulting from the Tax Cuts and Jobs Act enacted in December 2017. ASU 2018-02 is effective for fiscal years beginning after December 15, 2018 (our fiscal year 2020), including interim periods within that reporting period. The adoption of ASU 2018-02 is not expected to have a material impact on our financial position, results of operations or cash flows. In August 2017, the FASB issued ASU 2017-12, “Targeted Improvements to Accounting for Hedging Activities” (“ASU 2017-12”) to improve the financial reporting of hedging relationships to better portray the economic results of an entity's risk management activities in its financial statements. ASU 2017-12 is effective for fiscal years beginning after December 15, 2018 (our fiscal year 2020), including interim periods within that reporting period. The adoption of ASU 2017-12 is not expected to have a material impact on our financial position, results of operations or cash flows. In January 2017, the FASB issued ASU 2017-04, “(Topic 350) Simplifying the Test for Goodwill Impairment ,” (“ASU 2017-04”) to simplify the test for goodwill impairment. The revised guidance eliminates the existing Step 2 of the goodwill impairment test which required an entity to compute the implied fair value of its goodwill at the testing date in order to measure the amount of the impairment charge when the fair value of the reporting unit failed Step 1 of the goodwill impairment test. The guidance will be applied on a prospective basis on or after the effective date. ASU 2017-04 is effective for fiscal years beginning after December 31, 2019 (our fiscal year 2021) and early adoption is permitted for interim or annual goodwill impairment tests performed on testing dates after January 1, 2017. The adoption of ASU 2017-04 is not expected to have a material impact on our financial position, results of operations or cash flows. In February 2016, the FASB issued ASU 2016-02, “ (Topic 842) Leases ,” (“ASU 2016-02”). The new guidance requires the recording of assets and liabilities arising from leases on the balance sheet accompanied by enhanced qualitative and quantitative disclosures in the notes to the financial statements. ASU 2016-02 is effective for fiscal years beginning after December 31, 2018 (our fiscal year 2020), including interim periods within that reporting period. Early adoption is permitted as of the beginning of an interim or annual period. In July 2018, the FASB issued ASU 2018-10, “Codification Improvements to Topic 842, Leases,” and ASU 2018-11, “Leases (Topic 842) Targeted Improvements,” and in December 2018, the FASB issued ASU 2018-20, “Narrow-Scope Improvements for Lessors.” These ASUs provide narrow adjustments relating to ASU 2016-02 and improvements to comparative reporting requirements for initial adoption and for separating components of a contract for lessors. We are currently in the process of evaluating the impact of the collective standard (“ASC 842”) on our financial position, results of operations and cash flows.

Acquisitions (Tables)

Acquisitions (Tables)	6 Months Ended
	Jan. 31, 2019
Business Combinations [Abstract]
Schedule of purchase price allocated to the assets acquired and assumed liabilities based on estimated fair values	The following table presents our purchase price allocations of our material acquisitions: 2019 2018 Purchase Price Allocation CES Business (1) Aexis (1) BHT Group (1) (Preliminary) (Preliminary) (Final) Purchase Price: Cash paid $ 17,047 $ 20,308 $ 60,216 Fair value of contingent consideration — 1,292 — Total $ 17,047 $ 21,600 $ 60,216 Allocation: Property and equipment 539 130 835 Amortizable intangible assets: Customer relationships 8,100 1,800 12,500 Technology — 4,600 6,200 Goodwill 6,137 17,092 40,934 Deferred income taxes — (1,639 ) (5,881 ) Other working capital 2,271 909 5,628 Contingent consideration — (1,292 ) — Total $ 17,047 $ 21,600 $ 60,216 _______________________________________________ (1) The excess purchase price over net assets acquired was assigned to goodwill, all of which is deductible for income tax purposes.

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jan. 31, 2019
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of the income statement components of stock-based compensation expense recognized in the Condensed Consolidated Statements of Income	The following table shows the components of stock-based compensation expense recognized in the condensed consolidated statements of income: Three Months Ended January 31, Six Months Ended January 31, 2019 2018 2019 2018 Cost of sales $ 287 $ 181 $ 524 $ 296 Operating expenses: Selling 575 264 1,146 629 General and administrative 2,665 2,257 4,375 3,590 Research and development 60 37 118 75 Total operating expenses 3,300 2,558 5,639 4,294 Stock-based compensation expense $ 3,587 $ 2,739 $ 6,163 $ 4,590
Schedule of weighted-average assumptions used to estimate fair value of stock options	We determined the fair value of our market-based restricted stock awards using a Monte Carlo simulation on the date of grant using the following assumptions: Six Months Ended January 31, 2019 2018 Volatility of common stock 27.54 % 26.60 % Average volatility of peer companies 36.55 % 33.72 % Average correlation coefficient of peer companies 27.18 % 32.26 % Risk-free interest rate 2.93 % 1.62 %
Summary of nonvested stock award activity	A summary of nonvested stock award activity for the six months ended January 31, 2019 follows: Number of Time-based Awards Number of Performance-based Awards Number of Market-based Awards Number of Total Awards Weighted Average Fair Value July 31, 2018 168,320 26,076 17,710 212,106 $ 88.87 Granted 122,478 27,231 16,765 166,474 $ 91.63 Vested (1) (85,308 ) (10,284 ) — (95,592 ) $ 76.71 Forfeited (6,865 ) (723 ) — (7,588 ) $ 89.13 January 31, 2019 198,625 42,300 34,475 275,400 $ 94.99 _______________________________________________ (1) The aggregate fair value of all nonvested stock awards which vested was approximately $7,335 .
Summary of stock option activity	A summary of stock option activity for the six months ended January 31, 2019 follows: Number of shares Weighted Average Exercise Price Weighted Average Contractual Life Remaining (Years) Aggregate Intrinsic Value Outstanding at July 31, 2018 70,000 $ 38.60 Exercised (30,000 ) $ 31.81 Outstanding at January 31, 2019 40,000 $ 43.70 1.07 $ 1,509 Exercisable at January 31, 2019 40,000 $ 43.70 1.07 $ 1,509

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jan. 31, 2019
Revenue from Contract with Customer [Abstract]
Schedule of net sales disaggregated by geography and product line	The following table gives information as to the net sales disaggregated by geography and product line: Three Months Ended January 31, Six Months Ended January 31, Net sales by geography 2019 2018 2019 2018 (1) United States $ 165,164 $ 157,708 $ 334,102 $ 318,648 Europe/Africa/Middle East 34,319 32,498 66,333 60,553 Asia/Pacific 15,568 12,987 31,320 26,849 Canada 8,138 8,318 15,509 16,796 Latin America/South America 1,349 1,523 2,863 2,954 Total $ 224,538 $ 213,034 $ 450,127 $ 425,800 Net sales by product line Capital equipment $ 57,387 $ 59,071 $ 115,519 $ 118,240 Consumables 135,731 127,413 272,552 255,807 Product service 30,525 26,550 60,354 51,351 All other (2) 895 — 1,702 402 Total $ 224,538 $ 213,034 $ 450,127 $ 425,800 _______________________________________________ (1) As noted above, prior year amounts have not been adjusted under the modified retrospective method. (2) Primarily includes software licensing revenues.
Schedule of contract liabilities activity	A summary of contract liabilities activity for the six months ended January 31, 2019 follows: Contract Liabilities Balance, August 1, 2018 $ 29,015 Revenue deferred in current year 31,525 Deferred revenue recognized (32,444 ) Foreign currency translation (443 ) Balance, January 31, 2019 27,653 Contract liabilities included in Other long-term liabilities (517 ) Deferred revenue $ 27,136

Inventories, Net (Tables)

Inventories, Net (Tables)	6 Months Ended
	Jan. 31, 2019
Inventory Disclosure [Abstract]
Summary of inventories	A summary of inventories is as follows: January 31, 2019 July 31, 2018 Raw materials and parts $ 57,812 $ 49,054 Work-in-process 11,573 13,189 Finished goods 55,738 53,948 Reserve for excess and obsolete inventory (9,237 ) (8,599 ) Total $ 115,886 $ 107,592

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jan. 31, 2019
Fair Value Disclosures [Abstract]
Schedule of fair values of financial instruments measured on a recurring basis	The fair values of our financial instruments measured on a recurring basis were categorized as follows: January 31, 2019 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Money markets $ 104 $ — $ — $ 104 Total assets $ 104 $ — $ — $ 104 Liabilities: Other long-term liabilities: Contingent consideration — — 1,352 1,352 Total liabilities $ — $ — $ 1,352 $ 1,352 July 31, 2018 Level 1 Level 2 Level 3 Total Assets: Cash and cash equivalents: Money markets $ 104 $ — $ — $ 104 Total assets $ 104 $ — $ — $ 104 Liabilities: Other long-term liabilities: Contingent obligation — — 1,298 1,298 Total liabilities $ — $ — $ 1,298 $ 1,298
Level 3 activity of financial liabilities	A reconciliation of our liabilities that are measured and recorded at fair value on a recurring basis using significant unobservable inputs (Level 3) is as follows: Aexis Contingent Consideration Balance, July 31, 2018 $ 1,298 Net activity 54 Balance, January 31, 2019 $ 1,352

Intangibles and Goodwill (Table

Intangibles and Goodwill (Tables)	6 Months Ended
	Jan. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets	Our intangible assets consist of the following: January 31, 2019 July 31, 2018 Gross Accumulated Amortization Net Gross Accumulated Amortization Net Intangible assets with finite lives: Customer relationships (1) $ 135,330 $ (46,153 ) $ 89,177 $ 133,347 $ (45,618 ) $ 87,729 Technology (1) 58,728 (20,144 ) 38,584 54,585 (19,836 ) 34,749 Brand names (1) 6,919 (2,944 ) 3,975 8,141 (3,857 ) 4,284 Non-compete agreements (1) 2,880 (1,555 ) 1,325 3,060 (1,628 ) 1,432 Patents and other registrations 2,987 (1,195 ) 1,792 2,826 (1,179 ) 1,647 206,844 (71,991 ) 134,853 201,959 (72,118 ) 129,841 Trademarks and tradenames 6,695 — 6,695 7,520 — 7,520 Total intangible assets $ 213,539 $ (71,991 ) $ 141,548 $ 209,479 $ (72,118 ) $ 137,361 _______________________________________________ (1) During the six months ended January 31, 2019 , we wrote off $10,319 of fully amortized intangible assets.
Schedule of changes in goodwill	Goodwill changed during the six months ended January 31, 2019 as follows: Medical Life Sciences Dental Dialysis Total Goodwill Balance, July 31, 2018 $ 186,690 $ 58,925 $ 114,279 $ 8,133 $ 368,027 Acquisitions — 6,137 — — 6,137 Divestitures — (495 ) — — (495 ) Foreign currency translation (2,562 ) (92 ) — — (2,654 ) Balance, January 31, 2019 $ 184,128 $ 64,475 $ 114,279 $ 8,133 $ 371,015

Financing Arrangements (Tables)

Financing Arrangements (Tables)	6 Months Ended
	Jan. 31, 2019
Debt Disclosure [Abstract]
Schedule of Long-term Debt Instruments	Our long-term debt consists of the following: January 31, 2019 July 31, 2018 Revolving credit loans outstanding $ 45,000 $ — Tranche A term loan outstanding 195,000 200,000 Unamortized debt issuance costs (2,423 ) (2,698 ) Total long-term debt, net of unamortized debt issuance costs 237,577 197,302 Current portion of long-term debt (10,000 ) (10,000 ) Long-term debt, net of unamortized debt issuance costs and excluding current portion $ 227,577 $ 187,302

Earnings Per Common Share (Tabl

Earnings Per Common Share (Tables)	6 Months Ended
	Jan. 31, 2019
Earnings Per Share [Abstract]
Schedule of computation of basic and diluted EPS available to stockholders of common stock (excluding participating securities)	The following table sets forth the computation of basic and diluted EPS available to stockholders of common stock (excluding participating securities): Three Months Ended January 31, Six Months Ended January 31, 2019 2018 2019 2018 Numerator for basic and diluted earnings per share: Net income $ 18,800 $ 32,488 $ 38,042 $ 55,417 Less income allocated to participating securities (16 ) (107 ) (49 ) (225 ) Net income available to common shareholders $ 18,784 $ 32,381 $ 37,993 $ 55,192 Denominator for basic and diluted earnings per share, adjusted for participating securities: Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock 41,667,955 41,578,483 41,660,095 41,549,570 Dilutive effect of stock awards using the treasury stock method and the average market price for the year 18,088 55,561 41,558 60,897 Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock 41,686,043 41,634,044 41,701,653 41,610,467 Earnings per share attributable to common stock: Basic earnings per share $ 0.45 $ 0.78 $ 0.91 $ 1.33 Diluted earnings per share $ 0.45 $ 0.78 $ 0.91 $ 1.33 Stock options excluded from weighted average dilutive common shares because their inclusion would have been anti-dilutive — — — —
Schedule of reconciliation of weighted average number of shares and common stock equivalents attributable to common stock to the Company's total weighted average number of shares and common stock equivalents including participating securities	A reconciliation of weighted average number of shares and common stock equivalents attributable to common stock, as determined above, to our total weighted average number of shares and common stock equivalents, including participating securities, is set forth in the following table: Three Months Ended January 31, Six Months Ended January 31, 2019 2018 2019 2018 Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock 41,686,043 41,634,044 41,701,653 41,610,467 Participating securities 33,400 138,508 55,436 172,205 Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities 41,719,443 41,772,552 41,757,089 41,782,672

Income Taxes (Tables)

Income Taxes (Tables)	6 Months Ended
	Jan. 31, 2019
Income Tax Disclosure [Abstract]
Reconciliation of consolidated effective income tax rate between periods	A reconciliation of the consolidated effective income tax rate is as follows: Three Months Ended Six Months Ended Effective Rate, January 31, 2018 (3.6 )% 11.9 % Deferred tax revaluation 27.5 % 13.7 % U.S. federal statutory rate decrease (5.8 )% (5.8 )% Prior quarter true-up due to U.S. federal statutory rate decrease 8.2 % — % Foreign operations (1.8 )% 1.6 % State taxes 0.1 % 0.5 % Excess tax benefit (0.9 )% 1.2 % Other 2.0 % 2.2 % Effective Rate, January 31, 2019 25.7 % 25.3 %

Accumulated Other Comprehensi_2

Accumulated Other Comprehensive Loss (Tables)	6 Months Ended
	Jan. 31, 2019
Accumulated Other Comprehensive Income (Loss)
Schedule of the components and changes in accumulated other comprehensive income (loss)	The components and changes in accumulated other comprehensive loss were as follows: Three Months Ended January 31, Six Months Ended January 31, 2019 2018 2019 2018 Beginning balance $ (16,679 ) $ (11,133 ) $ (11,456 ) $ (9,900 ) Other comprehensive (income) loss due to foreign currency translation (417 ) 12,379 (5,640 ) 11,146 Ending balance $ (17,096 ) $ 1,246 $ (17,096 ) $ 1,246

Reportable Segments (Tables)

Reportable Segments (Tables)	6 Months Ended
	Jan. 31, 2019
Segment Reporting [Abstract]
Information as to reportable segments	Information as to reportable segments is summarized below: Three Months Ended January 31, Six Months Ended January 31, Net sales 2019 2018 2019 2018 Medical $ 128,580 $ 116,665 $ 256,132 $ 229,050 Life Sciences 51,869 52,337 105,214 107,107 Dental 35,933 36,090 72,561 73,767 Dialysis 8,156 7,942 16,220 15,876 Total net sales $ 224,538 $ 213,034 $ 450,127 $ 425,800 Three Months Ended January 31, Six Months Ended January 31, Income from operations 2019 2018 2019 2018 Medical $ 25,525 $ 24,463 $ 50,736 $ 44,147 Life Sciences 7,323 8,583 13,654 18,958 Dental 4,888 6,558 10,813 15,233 Dialysis 1,193 1,918 2,577 4,017 38,929 41,522 77,780 82,355 General corporate expenses 12,733 9,040 23,906 18,239 Total income from operations $ 26,196 $ 32,482 $ 53,874 $ 64,116

Acquisitions - Omnia (Details)

Acquisitions - Omnia (Details) - USD ($)	Feb. 01, 2019	Jan. 31, 2019	Jan. 31, 2018
Business Acquisition [Line Items]
Acquisition of businesses, net of cash acquired		$ 24,047,000	$ 64,287,000
Subsequent Event
Business Acquisition [Line Items]
Acquisition of businesses, net of cash acquired	$ 23,971,000
Subsequent Event | Omnia
Business Acquisition [Line Items]
Total consideration for the transaction, excluding acquisition-related costs	27,190,000
Stock consideration	3,219,000
Subsequent Event | Minimum | Omnia
Business Acquisition [Line Items]
Contingent consideration	0
Subsequent Event | Maximum | Omnia
Business Acquisition [Line Items]
Contingent consideration	$ 5,800,000

Acquisitions Acquisitions - CES

Acquisitions Acquisitions - CES Business (Details) - USD ($) $ in Thousands	Aug. 01, 2018	Jan. 31, 2019
CES Business
Business Acquisition [Line Items]
Total consideration for the transaction, excluding acquisition-related costs	$ 17,047	$ 17,047

Acquisitions - Aexis Medical (D

Acquisitions - Aexis Medical (Details) - USD ($)	Mar. 21, 2018	Jan. 31, 2019	Jan. 31, 2018	Jul. 31, 2018
Business Acquisition [Line Items]
Acquisition of businesses, net of cash acquired		$ 24,047,000	$ 64,287,000
Aexis
Business Acquisition [Line Items]
Total consideration for the transaction, excluding acquisition-related costs	$ 21,600,000			$ 21,600,000
Acquisition of businesses, net of cash acquired	20,308,000
Contingent consideration	1,292,000			$ 1,292,000
Minimum | Aexis
Business Acquisition [Line Items]
Contingent consideration	0
Maximum | Aexis
Business Acquisition [Line Items]
Contingent consideration	$ 1,850,000

Acquisitions - BHT Group (Detai

Acquisitions - BHT Group (Details) - USD ($) $ in Thousands	Aug. 23, 2018	Jul. 31, 2018
BHT Group
Business Acquisition [Line Items]
Total consideration for the transaction, excluding acquisition-related costs	$ 60,216	$ 60,216

Acquisitions - Summary of Acqui

Acquisitions - Summary of Acquisitions (Details) - USD ($) $ in Thousands	Aug. 23, 2018	Aug. 01, 2018	Mar. 21, 2018	Jan. 31, 2019	Jul. 31, 2018
Business Acquisition [Line Items]
Goodwill				$ 371,015	$ 368,027
CES Business
Business Acquisition [Line Items]
Cash paid				17,047
Fair value of contingent consideration				0
Total		$ 17,047		17,047
Property and equipment				539
Goodwill				6,137
Deferred income taxes				0
Other working capital				2,271
Contingent consideration				0
Total				17,047
CES Business | Customer relationships
Business Acquisition [Line Items]
Amortizable intangible assets:				8,100
CES Business | Technology
Business Acquisition [Line Items]
Amortizable intangible assets:				$ 0
Aexis
Business Acquisition [Line Items]
Cash paid					20,308
Fair value of contingent consideration					1,292
Total			$ 21,600		21,600
Property and equipment					130
Goodwill					17,092
Deferred income taxes					(1,639)
Other working capital					909
Contingent consideration			$ (1,292)		(1,292)
Total					21,600
Aexis | Customer relationships
Business Acquisition [Line Items]
Amortizable intangible assets:					1,800
Aexis | Technology
Business Acquisition [Line Items]
Amortizable intangible assets:					4,600
BHT Group
Business Acquisition [Line Items]
Cash paid					60,216
Fair value of contingent consideration					0
Total	$ 60,216				60,216
Property and equipment					835
Goodwill					40,934
Deferred income taxes					(5,881)
Other working capital					5,628
Contingent consideration					0
Total					60,216
BHT Group | Customer relationships
Business Acquisition [Line Items]
Amortizable intangible assets:					12,500
BHT Group | Technology
Business Acquisition [Line Items]
Amortizable intangible assets:					$ 6,200

Stock-Based Compensation - Narr

Stock-Based Compensation - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jul. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding unvested restricted stock shares (in shares)	275,400		212,106
Outstanding options (in shares)	40,000		70,000
Total unrecognized stock-based compensation cost	$ 19,881
Remaining weighted average period for unrecognized compensation cost	19 months
Number of options exercised (in shares)	30,000
Deduction in income tax due to exercise of options and vesting of restricted stock	$ 3,059	$ 3,406
Reduction in income tax expense over the equity awards' vesting period	2,062	1,394
Excess tax benefit	$ 997	$ 2,012
Employee and directors stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options vested during period (in shares)	5,000
Aggregate fair value of all options vested	$ 277
Number of options exercised (in shares)	30,000
Aggregate fair value of exercised options	$ 1,787
2016 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding unvested restricted stock shares (in shares)	275,400
Outstanding options (in shares)	0
Shares available under Plan (in shares)	815,698
2006 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Outstanding options (in shares)	40,000

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income
Stock-based compensation expense	$ 3,587	$ 2,739	$ 6,163	$ 4,590
Cost of sales
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income
Stock-based compensation expense	287	181	524	296
Total operating expenses
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income
Stock-based compensation expense	3,300	2,558	5,639	4,294
Selling
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income
Stock-based compensation expense	575	264	1,146	629
General and administrative
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income
Stock-based compensation expense	2,665	2,257	4,375	3,590
Research and development
Income statement components of stock-based compensation expense recognized in Consolidated Statements of Income
Stock-based compensation expense	$ 60	$ 37	$ 118	$ 75

Stock-Based Compensation - Fair

Stock-Based Compensation - Fair Value Monte Carlo Simulation (Details) - Restricted Stock	6 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Volatility of common stock	27.54%	26.60%
Average volatility of peer companies	36.55%	33.72%
Average correlation coefficient of peer companies	27.18%	32.26%
Risk-free interest rate	2.93%	1.62%

Stock-Based Compensation - Nonv

Stock-Based Compensation - Nonvested Stock Award Activity (Details) $ / shares in Units, $ in Thousands	6 Months Ended
	Jan. 31, 2019USD ($)$ / sharesshares
Number of Shares
Nonvested stock awards at the beginning of the period (in shares)	212,106
Granted (in shares)	166,474
Vested (in shares)	(95,592)
Forfeited (in shares)	(7,588)
Nonvested stock awards at the end of the period (in shares)	275,400
Weighted Average Fair Value
Nonvested stock awards at the beginning of the period (in dollars per share) | $ / shares	$ 88.87
Granted (in dollars per share) | $ / shares	91.63
Vested (in dollars per share) | $ / shares	76.71
Forfeited (in dollars per share) | $ / shares	89.13
Nonvested stock awards at the end of the period (in dollars per share) | $ / shares	$ 94.99
Aggregate fair value of nonvested stock awards that vested | $	$ 7,335
Number of Time-based Awards
Number of Shares
Nonvested stock awards at the beginning of the period (in shares)	168,320
Granted (in shares)	122,478
Vested (in shares)	(85,308)
Forfeited (in shares)	(6,865)
Nonvested stock awards at the end of the period (in shares)	198,625
Number of Performance-based Awards
Number of Shares
Nonvested stock awards at the beginning of the period (in shares)	26,076
Granted (in shares)	27,231
Vested (in shares)	(10,284)
Forfeited (in shares)	(723)
Nonvested stock awards at the end of the period (in shares)	42,300
Number of Market-based Awards
Number of Shares
Nonvested stock awards at the beginning of the period (in shares)	17,710
Granted (in shares)	16,765
Vested (in shares)	0
Forfeited (in shares)	0
Nonvested stock awards at the end of the period (in shares)	34,475

Stock-Based Compensation - Stoc

Stock-Based Compensation - Stock Option Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jan. 31, 2019
Number of shares
Outstanding, beginning balance (in shares)	70,000
Exercised (in shares)	(30,000)
Outstanding, ending balance (in shares)	40,000
Weighted Average Exercise Price
Outstanding, beginning balance (in dollars per share)	$ 38.60
Exercised (in dollars per share)	31.81
Outstanding, ending balance (in dollars per share)	$ 43.70
Stock Option Activity, Additional Disclosures
Options outstanding, Weighted average contractual life remaining (in years)	12 months 27 days
Options outstanding, Aggregate intrinsic value (in dollars)	$ 1,509
Options exercisable, number of options (in shares)	40,000
Options exercisable, Weighted average exercise price (in dollars per share)	$ 43.70
Options exercisable, Weighted average contractual life remaining (in years)	12 months 27 days
Options exercisable, Aggregate intrinsic value (in dollars)	$ 1,509

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details) - Accounting Standards Update 2014-09 $ in Thousands	Aug. 01, 2018USD ($)
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative impact of 606 adoption	$ 865
Retained Earnings
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Cumulative impact of 606 adoption	$ 865

Revenue Recognition - Summary o

Revenue Recognition - Summary of net sales by geography and product line (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Disaggregation of Revenue [Line Items]
Net sales	$ 224,538	$ 213,034	$ 450,127	$ 425,800
United States
Disaggregation of Revenue [Line Items]
Net sales	165,164	157,708	334,102	318,648
Europe/Africa/Middle East
Disaggregation of Revenue [Line Items]
Net sales	34,319	32,498	66,333	60,553
Asia/Pacific
Disaggregation of Revenue [Line Items]
Net sales	15,568	12,987	31,320	26,849
Canada
Disaggregation of Revenue [Line Items]
Net sales	8,138	8,318	15,509	16,796
Latin America/South America
Disaggregation of Revenue [Line Items]
Net sales	1,349	1,523	2,863	2,954
Capital equipment
Disaggregation of Revenue [Line Items]
Net sales	57,387	59,071	115,519	118,240
Consumables
Disaggregation of Revenue [Line Items]
Net sales	135,731	127,413	272,552	255,807
Product service
Disaggregation of Revenue [Line Items]
Net sales	30,525	$ 26,550	60,354	51,351
All other
Disaggregation of Revenue [Line Items]
Net sales	$ 895		$ 1,702	$ 402

Revenue Recognition - Remaining

Revenue Recognition - Remaining Performance Obligations (Details) $ in Thousands	Jan. 31, 2019USD ($)
Revenue from Contract with Customer [Abstract]
Revenue, remaining performance obligation, amount	$ 67,281
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2019-02-01
Revenue from Contract with Customer [Abstract]
Revenue, remaining performance obligation, percentage	65.00%
Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]
Revenue, remaining performance obligation, expected timing of satisfaction, period	1 year 6 months

Revenue Recognition - Summary_2

Revenue Recognition - Summary of contract liabilities activity (Details) - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2019	Jul. 31, 2018
Contract Liabilities
Beginning Balance	$ 29,015
Revenue deferred in current year	31,525
Deferred revenue recognized	(32,444)
Foreign currency translation	(443)
Ending Balance	27,653
Contract liabilities included in Other long-term liabilities	(517)
Deferred revenue	$ 27,136	$ 28,614

Inventories, Net (Details)

Inventories, Net (Details) - USD ($) $ in Thousands	Jan. 31, 2019	Jul. 31, 2018
Inventory Disclosure [Abstract]
Raw materials and parts	$ 57,812	$ 49,054
Work-in-process	11,573	13,189
Finished goods	55,738	53,948
Reserve for excess and obsolete inventory	(9,237)	(8,599)
Total	$ 115,886	$ 107,592

Derivatives (Details)

Derivatives (Details) - Foreign currency forward contracts - Designated as hedging instrument - Fair value hedge instruments $ in Thousands	6 Months Ended
	Jan. 31, 2019USD ($)instrument	Jul. 31, 2018USD ($)instrument
Derivatives
Term of contracts	1 month
Number of contracts | instrument	7	8
Aggregate value of contracts | $	$ 62,904	$ 30,159

Fair Value Measurements - Narra

Fair Value Measurements - Narrative (Details) - Aexis - USD ($)	Jul. 31, 2018	Mar. 21, 2018
Assets and Liabilities Measured and Recorded at Fair Value on a Recurring Basis
Contingent consideration, low end of range		$ 0
Contingent consideration, high end of range		1,850,000
Contingent consideration	$ 1,292,000	$ 1,292,000

Fair Value Measurements - Hiera

Fair Value Measurements - Hierarchy Levels (Details) - Recurring basis - USD ($) $ in Thousands	Jan. 31, 2019	Jul. 31, 2018
Assets:
Total assets	$ 104	$ 104
Other long-term liabilities:
Contingent consideration	1,352	1,298
Total liabilities	1,352	1,298
Money markets
Assets:
Money markets	104	104
Level 1
Assets:
Total assets	104	104
Other long-term liabilities:
Contingent consideration	0	0
Total liabilities	0	0
Level 1 | Money markets
Assets:
Money markets	104	104
Level 2
Assets:
Total assets	0	0
Other long-term liabilities:
Contingent consideration	0	0
Total liabilities	0	0
Level 2 | Money markets
Assets:
Money markets	0	0
Level 3
Assets:
Total assets	0	0
Other long-term liabilities:
Contingent consideration	1,352	1,298
Total liabilities	1,352	1,298
Level 3 | Money markets
Assets:
Money markets	$ 0	$ 0

Fair Value Measurements - Level

Fair Value Measurements - Level 3 Rollforward (Details) - Aexis $ in Thousands	6 Months Ended
	Jan. 31, 2019USD ($)
Fair Value, Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation, Calculation [Roll Forward]
Beginning balance	$ 1,298
Net activity	54
Ending Balance	$ 1,352

Intangibles and Goodwill - Inta

Intangibles and Goodwill - Intangible Assets Summary (Details) - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2019	Jul. 31, 2018
Intangible assets with finite lives:
Gross	$ 206,844	$ 201,959
Accumulated Amortization	(71,991)	(72,118)
Net	134,853	129,841
Intangible assets with indefinite lives:
Trademarks and tradenames	6,695	7,520
Total intangible assets
Gross	213,539	209,479
Accumulated Amortization	(71,991)	(72,118)
Net	141,548	137,361
Write-off of fully impaired customer relationships and brand names	10,319
Customer relationships
Intangible assets with finite lives:
Gross	135,330	133,347
Accumulated Amortization	(46,153)	(45,618)
Net	89,177	87,729
Total intangible assets
Accumulated Amortization	(46,153)	(45,618)
Technology
Intangible assets with finite lives:
Gross	58,728	54,585
Accumulated Amortization	(20,144)	(19,836)
Net	38,584	34,749
Total intangible assets
Accumulated Amortization	(20,144)	(19,836)
Brand names
Intangible assets with finite lives:
Gross	6,919	8,141
Accumulated Amortization	(2,944)	(3,857)
Net	3,975	4,284
Total intangible assets
Accumulated Amortization	(2,944)	(3,857)
Non-compete agreements
Intangible assets with finite lives:
Gross	2,880	3,060
Accumulated Amortization	(1,555)	(1,628)
Net	1,325	1,432
Total intangible assets
Accumulated Amortization	(1,555)	(1,628)
Patents and other registrations
Intangible assets with finite lives:
Gross	2,987	2,826
Accumulated Amortization	(1,195)	(1,179)
Net	1,792	1,647
Total intangible assets
Accumulated Amortization	$ (1,195)	$ (1,179)

Intangibles and Goodwill - Narr

Intangibles and Goodwill - Narrative (Details) - USD ($) $ in Thousands	6 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Goodwill and Intangible Assets Disclosure [Abstract]
Amortization expense	$ 10,552	$ 8,412
Future amortization - remainder of 2019	9,611
Future amortization - 2020	17,384
Future amortization - 2021	17,077
Future amortization - 2022	16,695
Future amortization - 2023	15,665
Future amortization - 2024	$ 14,786

Intangibles and Goodwill - Good

Intangibles and Goodwill - Goodwill Rollforward (Details) $ in Thousands	6 Months Ended
	Jan. 31, 2019USD ($)
Changes in Goodwill
Balance at the beginning of the period	$ 368,027
Acquisitions	6,137
Divestitures	(495)
Foreign currency translation	(2,654)
Balance at the end of the period	371,015
Medical
Changes in Goodwill
Balance at the beginning of the period	186,690
Acquisitions	0
Divestitures	0
Foreign currency translation	(2,562)
Balance at the end of the period	184,128
Life Sciences
Changes in Goodwill
Balance at the beginning of the period	58,925
Acquisitions	6,137
Divestitures	(495)
Foreign currency translation	(92)
Balance at the end of the period	64,475
Dental
Changes in Goodwill
Balance at the beginning of the period	114,279
Acquisitions	0
Foreign currency translation	0
Balance at the end of the period	114,279
Dialysis
Changes in Goodwill
Balance at the beginning of the period	8,133
Acquisitions	0
Foreign currency translation	0
Balance at the end of the period	$ 8,133

Financing Arrangements - Schedu

Financing Arrangements - Schedule of long-term debt (Details) - USD ($)	Jan. 31, 2019	Jul. 31, 2018	Jun. 28, 2018
Debt Instrument [Line Items]
Total long-term debt, net of unamortized debt issuance costs	$ 237,577,000	$ 197,302,000
Current portion of long-term debt	(10,000,000)	(10,000,000)
Long-term debt, net of unamortized debt issuance costs and excluding current portion	227,577,000	187,302,000
Line of Credit
Debt Instrument [Line Items]
Unamortized debt issuance costs	(2,423,000)	(2,698,000)
Revolving credit loan | Line of Credit
Debt Instrument [Line Items]
Loans outstanding	45,000,000	0	$ 400,000,000
Tranche A term loan | Line of Credit
Debt Instrument [Line Items]
Loans outstanding	$ 195,000,000	$ 200,000,000	$ 200,000,000

Financing Arrangements - Narrat

Financing Arrangements - Narrative (Details) - Line of Credit - USD ($)	6 Months Ended
	Jan. 31, 2019	Jul. 31, 2018	Jun. 28, 2018
Debt Instrument [Line Items]
Maximum borrowing capacity			$ 300,000,000
Fees on unused portion of credit facilities (as a percent)	0.20%
Shares of foreign subsidiaries pledged as security (as a percent)	65.00%
Minimum
Debt Instrument [Line Items]
Fees on unused portion of credit facilities (as a percent)	0.20%
Maximum
Debt Instrument [Line Items]
Fees on unused portion of credit facilities (as a percent)	0.35%
Lender's base rate
Debt Instrument [Line Items]
Margin on reference rate (as a percent)	0.25%
Reference rate (as a percent)	5.75%
Lender's base rate | Minimum
Debt Instrument [Line Items]
Margin on reference rate (as a percent)	0.00%
Lender's base rate | Maximum
Debt Instrument [Line Items]
Margin on reference rate (as a percent)	1.00%
LIBOR
Debt Instrument [Line Items]
Margin on reference rate (as a percent)	1.25%
LIBOR | Minimum
Debt Instrument [Line Items]
Margin on reference rate (as a percent)	1.00%
Reference rate (as a percent)	3.77%
LIBOR | Maximum
Debt Instrument [Line Items]
Margin on reference rate (as a percent)	2.00%
Tranche A term loan
Debt Instrument [Line Items]
Loans outstanding	$ 195,000,000	$ 200,000,000	200,000,000
Term loan borrowings outstanding	195,000,000
Principal amortization, periodic payment due 2019, 2020, 2021, and 2022	10,000,000
Balance due and payable at maturity in 2023	160,000,000
Principal payment made	$ 5,000,000
Interest rate (as a percent)	3.75%
Revolving credit loan
Debt Instrument [Line Items]
Loans outstanding	$ 45,000,000	$ 0	$ 400,000,000

Commitments and Contingencies -

Commitments and Contingencies - Narrative (Details) - USD ($) $ in Thousands	Jan. 31, 2019	Oct. 31, 2017	Jul. 31, 2017
Aexis
Business Acquisition [Line Items]
Assumed contingent obligation	$ 1,352
Jet Prep Ltd.
Business Acquisition [Line Items]
Assumed contingent obligation		$ 0	$ 1,138

Earnings Per Common Share - Com

Earnings Per Common Share - Computation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jan. 31, 2019	Oct. 31, 2018	Jan. 31, 2018	Oct. 31, 2017	Jan. 31, 2019	Jan. 31, 2018
Numerator for basic and diluted earnings per share:
Net income	$ 18,800	$ 19,242	$ 32,488	$ 22,929	$ 38,042	$ 55,417
Less income allocated to participating securities	(16)		(107)		(49)	(225)
Net income available to common shareholders	$ 18,784		$ 32,381		$ 37,993	$ 55,192
Denominator for basic and diluted earnings per share, adjusted for participating securities:
Denominator for basic earnings per share - weighted average number of shares outstanding attributable to common stock (in shares)	41,667,955		41,578,483		41,660,095	41,549,570
Dilutive effect of stock awards using the treasury stock method and the average market price for the year (in shares)	18,088		55,561		41,558	60,897
Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock (in shares)	41,686,043		41,634,044		41,701,653	41,610,467
Earnings per share attributable to common stock:
Basic earnings per share (in dollars per share)	$ 0.45		$ 0.78		$ 0.91	$ 1.33
Diluted earnings per share (in dollars per share)	$ 0.45		$ 0.78		$ 0.91	$ 1.33
Stock options excluded from weighted average dilutive common shares outstanding because their inclusion would have been anti-dilutive (in shares)	0		0		0	0

Earnings Per Common Share - Wei

Earnings Per Common Share - Weighted Average Shares (Details) - shares	3 Months Ended		6 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Reconciliation of weighted average number of shares and common stock equivalents attributable to common stock, to the entity's total weighted average number of shares and common stock equivalents, including participating securities
Denominator for diluted earnings per share - weighted average number of shares and common stock equivalents attributable to common stock (in shares)	41,686,043	41,634,044	41,701,653	41,610,467
Participating securities (in shares)	33,400	138,508	55,436	172,205
Total weighted average number of shares and common stock equivalents attributable to both common stock and participating securities (in shares)	41,719,443	41,772,552	41,757,089	41,782,672

Income Taxes - Narrative (Detai

Income Taxes - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jul. 31, 2018	Jan. 31, 2019
Income Tax Disclosure [Abstract]
TCJA, Revaluation of deferred tax assets and liabilities, provisional income tax expense (benefit)	$ 8,657
Effective blended tax rate		26.90%

Income Taxes - Reconciliation (

Income Taxes - Reconciliation (Details)	3 Months Ended		6 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Income Tax Disclosure [Abstract]
Effective Rate	25.70%	(3.60%)	25.30%	11.90%
Deferred tax revaluation	27.50%		13.70%
U.S. federal statutory rate decrease	(5.80%)		(5.80%)
Prior quarter true-up due to U.S. federal statutory rate decrease	8.20%		0.00%
Foreign operations	(1.80%)		1.60%
State taxes	0.10%		0.50%
Excess tax benefit	(0.90%)		1.20%
Other	2.00%		2.20%

Accumulated Other Comprehensi_3

Accumulated Other Comprehensive Loss (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Components and changes in accumulated other comprehensive (loss) income
Beginning balance	$ (16,679)	$ (11,133)	$ (11,456)	$ (9,900)
Other comprehensive (income) loss due to foreign currency translation	(417)	12,379	(5,640)	11,146
Ending balance	$ (17,096)	$ 1,246	$ (17,096)	$ 1,246

Reportable Segments - Concentra

Reportable Segments - Concentration Risk (Details) - Segment sales - Customer concentration	6 Months Ended
	Jan. 31, 2019	Jan. 31, 2018
Life Sciences | Two customers
Concentration risk
Concentration risk within segment (as a percent)	42.50%	51.30%
Dental | Three customers
Concentration risk
Concentration risk within segment (as a percent)	47.90%	48.30%
Dialysis | Two customers
Concentration risk
Concentration risk within segment (as a percent)	20.60%	38.70%

Reportable Segments - Results (

Reportable Segments - Results (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jan. 31, 2019	Jan. 31, 2018	Jan. 31, 2019	Jan. 31, 2018
Information as to operating segments
Net sales	$ 224,538	$ 213,034	$ 450,127	$ 425,800
Segment operating income	26,196	32,482	53,874	64,116
General corporate expenses	37,358	32,188	73,893	64,284
Operating Segment
Information as to operating segments
Segment operating income	38,929	41,522	77,780	82,355
Medical
Information as to operating segments
Net sales	128,580	116,665	256,132	229,050
Medical | Operating Segment
Information as to operating segments
Segment operating income	25,525	24,463	50,736	44,147
Life Sciences
Information as to operating segments
Net sales	51,869	52,337	105,214	107,107
Life Sciences | Operating Segment
Information as to operating segments
Segment operating income	7,323	8,583	13,654	18,958
Dental
Information as to operating segments
Net sales	35,933	36,090	72,561	73,767
Dental | Operating Segment
Information as to operating segments
Segment operating income	4,888	6,558	10,813	15,233
Dialysis
Information as to operating segments
Net sales	8,156	7,942	16,220	15,876
Dialysis | Operating Segment
Information as to operating segments
Segment operating income	1,193	1,918	2,577	4,017
General corporate | Segment reconciling items
Information as to operating segments
General corporate expenses	$ 12,733	$ 9,040	$ 23,906	$ 18,239